Investigating the effect of oxytocin on pancreatic endocrine functions by determining insulin and glucagon secretion within physiological ranges of plasma glucose.
Insulinotropic effects of oxytocin will be examined in 20 healthy men with body mass index (BMI) \< 27 kg/m2, during a graded glucose infusion test with concomitant intravenous infusion of synthetic oxytocin or placebo in a randomized, double-blinded design. This will determine the effect of oxytocin on glucose-stimulated insulin and glucagon secretion. Additional changes in plasma/serum concentrations of C-peptide, glucose, glucose-dependent insulinotropic polypeptid (GIP), glucagon-like peptide 1 (GLP-1), and lipids will be assessed.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
20
Center for Clinical Metabolic Research, Gentofte Hospital
Hellerup, Capital Region, Denmark
RECRUITINGInsulin secretion - c-peptide
Insulin secretion, measured as percentual increase of area under the curve (AUC) for circulating c-peptide
Time frame: From time 0 to time 180 min
Glucose
measured as percentual increase of AUC for circulating levels
Time frame: From time 0 minutes to time 180 minutes
Insulin
measured as percentual increase of AUC for circulating levels
Time frame: From time 0 minutes to time 180 minutes
Glucagon
measured as percentual increase of AUC for circulating levels
Time frame: From time 0 minutes to time 180 minutes
GIP
measured as percentual increase of AUC for circulating levels
Time frame: From time 0 minutes to time 180 minutes
GLP-1
measured as percentual increase of AUC for circulating levels
Time frame: From time 0 minutes to time 180 minutes
Lipids
measured as percentual increase of AUCfor circulating levels
Time frame: From time 0 minutes to time 180 minutes
Cross-linked C-telopeptide of type I collagen( CTX)
measured as percentual increase of AUC for circulating levels
Time frame: From time 0 minutes to time 180 minutes
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Procollagen type I N-terminal propeptide (P1NP)
measured as percentual increase of AUC for circulating levels
Time frame: From time 0 minutes to time 180 minutes